A nurse is assisting in the care of a client who has a recent diagnosis of mild Crohn's disease. Which of the following medications should the nurse anticipate will be prescribed to help the client achieve remission?

Brief Introduction: For mild-to-moderate Crohn's disease, particularly when it affects the colon, the initial pharmacological goal is to reduce mucosal inflammation using aminosalicylates. These medications act locally on the intestinal lining to inhibit the production of pro-inflammatory mediators, facilitating the induction of remission without the immediate need for more potent, systemic immunosuppressants. Rationale: A. Alosetron is a selective serotonin 5-HT3 antagonist specifically indicated for women with severe irritable bowel syndrome with diarrhea (IBS-D). It is not used to treat the structural inflammatory damage seen in Crohn’s disease and carries a significant risk of ischemic colitis, requiring strict prescribing protocols. B. Infliximab is a tumor necrosis factor (TNF) blocker used for moderate-to-severe or fistulizing Crohn's disease. While highly effective, it is typically reserved for clients who do not respond to first-line therapies due to its systemic immunosuppressive effects and the risk of serious infections. C. Rifaximin is a non-absorbable antibiotic primarily used for traveler's diarrhea, hepatic encephalopathy, or small intestinal bacterial overgrowth (SIBO). While it may be used as an adjunct in some GI conditions, it is not a standard primary therapy for inducing remission in autoimmune-driven Crohn's disease. D. Sulfasalazine is a sulfonamide derivative that combines an antibacterial and an anti-inflammatory agent. The "sulfapyridine" carrier allows the active "5-aminosalicylic acid" to reach the distal intestines, where it effectively treats mildly active disease by suppressing the local inflammatory cascade within the bowel wall.